Named Bioactive Compounds · Compound
Rhododendrol (Phenolic Compound)
Moderate Evidencecompound3 PubMed Studies
Hermetica Superfood Encyclopedia
Rhododendrol is a toxic phenolic compound that causes permanent skin depigmentation by generating cytotoxic metabolites through tyrosinase oxidation. This compound was banned from cosmetics in 2013 after causing widespread leukoderma in users.
Rhododendrol (RD), chemically 4-(4-hydroxyphenyl)-2-butanol, is a synthetic phenolic compound developed as a skin-whitening agent to inhibit melanin synthesis in cosmetics. It is not derived from any natural plant or organism but was commercially produced for topical use until 2013 when it was withdrawn due to causing leukoderma (depigmentation disorder) in users.
Clinical evidence consists entirely of studies documenting rhododendrol-induced leukoderma (RDL) rather than therapeutic trials. Japanese epidemiological surveys found ~50% incomplete leukoderma, 20-25% complete, and 25-30% mixed depigmentation patterns in affected cosmetic users. One pilot study (PMID: 30156328, n=11) tested topical bimatoprost for treating refractory RDL with only slight improvement in 4/10 patients.
No clinically studied therapeutic dosages exist as rhododendrol is contraindicated for any use. Research only documents adverse effects from cosmetic formulations (specific concentrations not reported in studies) that caused leukoderma. This compound should not be used in any form. Consult a healthcare provider before starting any new supplement.
Rhododendrol (4-(4-hydroxyphenyl)-2-butanol; C₁₀H₁₄O₂; MW 166.22 g/mol) is a phenolic compound naturally occurring in the bark and leaves of several plant species including Betula platyphylla (white birch), Acer nikoense, and certain Rhododendron species. It is NOT a nutritional compound and has no established dietary role. Key biochemical characteristics: • Contains a para-hydroxyphenyl moiety linked to a secondary alcohol group, classifying it as a simple phenylpropanoid-derived phenol. • Naturally present at trace concentrations in plant tissues (typically <0.1% dry weight in birch bark extracts). • Acts as a substrate for tyrosinase (EC 1.14.18.1), which catalyzes its oxidation to rhododendrol-quinone and rhododendrol-cyclic catechol metabolites — both demonstrated to be cytotoxic to melanocytes at micromolar concentrations (IC₅₀ ~50–200 µM in cultured human melanocytes). • No macronutrient value (no protein, carbohydrate, fat, or fiber contribution). • No vitamin or mineral content. • No established bioavailability data from oral ingestion in humans; historical use was exclusively topical (formerly at 2% w/w concentration in cosmetic formulations before withdrawal). • Lipophilicity: LogP ~1.5–1.8, allowing moderate skin penetration. • Structurally related to raspberry ketone (4-(4-hydroxyphenyl)-2-butanone) — rhododendrol is the reduced (alcohol) form. • No GRAS (Generally Recognized As Safe) status; not approved for food, supplement, or cosmetic use. This compound should NOT be consumed or applied; it is classified as a hazardous cosmetic ingredient following the 2013 Kanebo recall in Japan affecting approximately 19,605 confirmed cases of chemical leukoderma.
Rhododendrol undergoes tyrosinase-catalyzed oxidation in melanocytes, producing toxic quinone metabolites that damage cellular structures. These metabolites disrupt melanin synthesis pathways and cause selective melanocyte cytotoxicity. The compound interferes with normal tyrosinase function while paradoxically being metabolized by the same enzyme into harmful byproducts.
Nationwide surveys in Japan documented thousands of cases of rhododendrol-induced leukoderma following cosmetic use between 2008-2013. Clinical studies confirmed that 4-(4-hydroxyphenyl)-2-butanol concentrations as low as 0.1% caused depigmentation in susceptible individuals. Post-market surveillance revealed that approximately 19,000 consumers developed skin discoloration, with many cases showing irreversible pigment loss. No therapeutic applications have been established due to its documented toxicity profile.
Rhododendrol is contraindicated for all uses due to severe melanocyte toxicity and permanent skin depigmentation risks. The compound was withdrawn from all commercial products in 2013 following widespread adverse events. No safe exposure level has been established, and affected individuals may experience irreversible leukoderma. Pregnant and breastfeeding women should avoid any products containing this compound, though it is no longer commercially available.
